RxDoctor Payments Data

William Mustas

Physician Assistant · Waukesha, WINPI 1629080932

Payments from drug & device makers

$4,872in general payments, 2019–2025

Across 188 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$445
  • Pfizer$361
  • Teleflex LLC$272
  • Endo Pharmaceuticals Inc.$266
  • Halozyme Inc$250
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$4,35189%
  • Education$50310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,872 in reported general payments places this provider in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$9,407
Medicare patients
95
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron45$47,231
MyrbetriqMirabegron61$42,289
Tamsulosin Hcl183$1,736
Oxybutynin Chloride ErOxybutynin Chloride47$1,132
Testosterone Cypionate21$837
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$737
Cephalexin27$665
Ciprofloxacin Hcl39$366
Sildenafil Citrate16$210
Finasteride21$184
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$207$47,23145 claims
Astellas Pharma US IncMyrbetriq$1,485$42,28961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →